Alligator Bioscience

Per Norlén - born 1970, CEO – is a medical doctor with board certification in clinical pharmacology, and a PhD and associate professorship in clinical pharmacology at Lund University. Per Norlén has 25 years of research experience in pharmacology including 15 years of experience in clinical drug development. Employed since 2015 and member of the Management Team since 2010.

Other current positions: Chairman of A Bioscience Incentive AB. Board member of Atlas Therapeutics AB .

Holdings in Alligator: 118,000 shares, 200,000 warrants, 250,000 employee stock options in program 2016/2020 and 230,000 employee stock options in program 2018/2022.

Malin Carlsson - born 1968, Executive Vice President & Chief Operating Officer – is a medical doctor with board certification in clinical immunology at Lund University. Malin has 20 years of research experience in immunology 12 years of experience in clinical drug development. Employed since 2020 and member of the Management Team since 2020.

Other current positions: Board member of A Bioscience Incentive AB.

Holdings in Alligator: No holdings

Gayle Mills – Chief Business Officer – has B.S Business and an MBA from Santa Clara University, US. Gayle is a renowned business development professional with an extensive knowledge of the biotech and pharma landscape. She has a successful track record of executing large R&D collaborations and transactions and has held senior positions with Roche Bioscience, Abgenix, Inc. and Symphogen A/S. Employed since 2020 and member of the Executive Management Team since 2020.

Other current positions: Strategic Advisor to the CEO of Symphogen A/S; Business Development Consulting for Apexigen, OncoNano Medicine, Inc. and Mipsalus A/S.

Holdings in Alligator: No holdings

Marie Svensson – born 1964, Chief Financial Officer since 2020 – has a Bachelor of Science in accounting and a Master of Business Administration/Management from Lund University. Marie has more than 20 years of experience from various financial positions in the high-tech industry. Employed since 2020 and member of the Management Team since 2020.

Other current positions: None

Holdings in Alligator: 5000 shares

Peter Ellmark – born 1973, VP Discovery – holds a PhD and an associate professorship in Immunotechnology at Lund University. Peter has more than 15 years’ experience of developing antibodies for immunotherapy of cancer. Employed since 2008 and member of the Management Team since 2018.

Other current positions: None

Holdings in Alligator: 10,000 shares, 50,000 warrants, 50,000 employee stock options in program 2016/2020 and 135,000 employee stock options in program 2018/2022.

Christina Furebring – born 1964, SVP Projects – holds a PhD in immune technology from Lund University. She is also a co-founder of the FIND technology which is a cornerstone of Alligator’s technology platform. Christina has more than 20 years’ experience of working on the optimization of proteins and antibodies. Employed since 2001 and member of the Management Team since 2001.

Other current positions: Deputy Board Member in A Bioscience Incentive AB and Atlas Therapeutics AB.

Holdings in Alligator: 100,000 shares, 120,000 warrants, 150,000 employee stock options in program 2016/2020 and 135,000 employee stock options in program 2018/2022.